Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price dropped 4.1% during mid-day trading on Wednesday . The stock traded as low as $37.52 and last traded at $37.83. Approximately 48,370 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 896,253 shares. The stock had previously closed at $39.45.
Analyst Ratings Changes
MTSR has been the topic of several recent analyst reports. Wells Fargo & Company initiated coverage on shares of Metsera in a report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Guggenheim lifted their price target on shares of Metsera from $56.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, June 10th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Metsera has an average rating of "Buy" and an average target price of $55.00.
Read Our Latest Analysis on Metsera
Metsera Stock Performance
The business's fifty day simple moving average is $31.84.
Metsera (NASDAQ:MTSR - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Hedge Funds Weigh In On Metsera
A number of hedge funds have recently bought and sold shares of the business. KLP Kapitalforvaltning AS purchased a new position in Metsera in the 2nd quarter worth about $122,000. Exchange Traded Concepts LLC purchased a new position in Metsera in the 2nd quarter worth about $1,153,000. Goldman Sachs Group Inc. purchased a new position in Metsera in the 1st quarter worth about $568,000. Rhumbline Advisers purchased a new position in Metsera in the 1st quarter worth about $520,000. Finally, Strs Ohio purchased a new position in Metsera in the 1st quarter worth about $76,000.
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access